GPCR nomenclature and pharmacology get a refreshed 2025/26 reference map
The 2025/26 Concise Guide to Pharmacology arrives as the seventh edition of a biennial reference series and keeps its focus squarely on one of drug discovery’s most productive target classes: G protein-coupled receptors. This edition sits within a broader pharmacology compendium that also covers ion channels, nuclear hormone receptors, catalytic receptors, enzymes, and transporters, but the GPCR section remains central because it anchors so much of modern receptor pharmacology, from cardiovascular signaling to neuropsychiatric and endocrine pathways.
The publication is not a trial report and does not ask a single therapeutic question. Its value lies elsewhere: in the curation of drug targets, receptor families, ligands, and nomenclature into a stable, citable snapshot of the field as it stood in mid-2025. In an area where online databases are updated continuously, a printed guide provides a fixed record that can be cited, compared, and archived without the uncertainty that comes with moving web content.
A stable reference for nearly 1,900 human drug targets
The 2025/26 edition summarizes the key pharmacological properties of around 1,900 human drug targets, with nearly 7,000 interactions involving about 4,400 ligands. Those figures convey the sheer scale of receptor pharmacology more effectively than any narrative description can. GPCRs alone account for an enormous share of clinically relevant signaling, and their pharmacology is defined not just by receptor presence, but by ligand selectivity, potency, family relationships, and the experimental tools needed to separate one target from another.
A concise guide is not concise because it is small. It is concise because it compresses a vast and technical literature into a clear, structured format that can be used at the bench, in teaching, and in target validation. The printed volume spans roughly 500 pages, which is a reminder that “concise” in this context refers to presentation style rather than superficial coverage. The intent is precision, not brevity for its own sake.
Researchers working on GPCRs often need a dependable answer to a practical question: which receptor is this ligand really hitting, and which compound best distinguishes one receptor subtype from the next? The guide addresses that need by assembling expert-curated recommendations for Gold Standard selective pharmacological tools. Those agents may be commercially available or supplied through donation, and they are selected to help identify individual targets or defined receptor families with greater confidence.
Why curated tool compounds still matter in receptor biology
GPCR pharmacology depends on more than receptor names. It depends on the ability to discriminate between closely related receptors, identify off-target effects, and validate signaling pathways with compounds whose selectivity is understood well enough to support interpretation. In that sense, the Guide functions as both a catalog and a quality-control instrument for the field. A receptor annotation without a reliable tool compound is often too thin to support mechanistic claims, while a carefully chosen ligand set can sharpen an entire line of investigation.
That matters particularly for families with dense subtype overlap and shared endogenous ligands, where functional readouts can blur into one another. A well-curated reference can reduce ambiguity before the first experiment begins. It can also prevent an overreliance on whichever reagent happens to be easiest to obtain, which is a familiar source of irreproducibility in receptor pharmacology.
The publication also serves a nomenclature function. Produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology, it provides official IUPHAR classification and naming for human drug targets where those assignments apply. For a field built on subtype distinctions, family relationships, and evolving receptor definitions, standardized naming is more than editorial housekeeping. It is the basis for coherent communication across laboratories, journals, and databases.
Mid-2025 as the cut point for a moving database
The 2025/26 edition is based on material current as of mid-2025 and supersedes the 2023/24 guide as well as earlier Guides to Receptors and Channels. That temporal cut point is important because pharmacology databases never really stop changing. New ligands appear, receptor annotations are refined, and evidence hierarchies are updated as new experiments accumulate. A stable edition freezes the field at a specific moment while still pointing readers back to the more expansive online resource for live updates.
The Guide to Pharmacology website remains the fuller source of receptor profiles, linked databases, and detailed pharmacological information. The print publication does not compete with that resource; it complements it. One offers depth and continuous revision, the other offers permanence and citation stability. In practical terms, the two formats serve different scientific habits. The website supports active exploration, while the guide provides an archival reference point that can stand beside a manuscript or grant application years later.
A classification system built for target discovery and comparison
GPCRs occupy a unique position in drug discovery because they are both biologically diverse and therapeutically tractable. They span sensory, autonomic, endocrine, and inflammatory signaling, which means the same receptor superfamily can influence vision, vascular tone, appetite, pain, and immune activity. A comparative guide is especially useful in that setting because it lets investigators see how one receptor family relates to another, where ligand selectivity is strong, and where pharmacology remains incomplete.
The broader structure of the publication is built around family-by-family comparison. Each section includes nomenclature guidance, concise summaries, the best available pharmacological tools, key references, and suggestions for further reading. For a field that depends on both historic continuity and frequent reannotation, that structure supports scientific memory. It also keeps the guide usable for readers who may need a fast answer rather than a full literature review.
The publication’s scale suggests a deeper point about contemporary pharmacology: target families are no longer isolated topics but interconnected systems of evidence. Ligands are assessed not only for activity, but for selectivity, utility, and place within a classification framework that can be shared internationally. In a receptor field as crowded as GPCR pharmacology, those shared standards are essential for keeping basic science, medicinal chemistry, and translational work aligned.
The enduring role of point-in-time pharmacology references
A static, citable volume may seem old-fashioned beside continuously updated digital databases, yet the format solves a real scientific problem. Continuous revision is valuable, but it can also make it hard to reconstruct the exact knowledge base that informed a paper or experiment at a specific time. The printed Concise Guide offers that fixed point in the literature. It documents what was known, how targets were classified, and which tools were recommended at a defined moment in 2025.
For GPCR research in particular, that archival function carries real weight. Receptor pharmacology advances through incremental refinements in nomenclature, selectivity, assay interpretation, and ligand validation. A guide that records those refinements in a stable format helps preserve continuity across editions and gives investigators a shared reference for the next round of receptor mapping, compound screening, and mechanism-based work. The remaining challenge is not access to information, but keeping the field’s standards synchronized as the underlying database continues to expand and change.